All News

2021

January

Featured News / Jan 15, 2021

Novartis Gene Therapies Recommits to Global Managed Access Program for 2021

Read More
Media Release / Jan 14, 2021

Novartis ligelizumab (QGE031) receives FDA Breakthrough Therapy designation for patients with chronic spontaneous urticaria (CSU)

Read More
Media Release / Jan 11, 2021

Novartis expands Oncology pipeline with in-licensing of tislelizumab from BeiGene

Read More
A woman, accompanied by her caregiver, shares her experiences with a doctor.
Story / Jan 11, 2021

Turning the sound up on patient voices in lung cancer research and development

Global Oncology Patient Insights Panels (GOPIPs) are giving patients and advocates a critical voice in advancing lung cancer trials.

Read More
Chinese family embracing exercise and the outdoors
Story / Jan 07, 2021

AI Nurse evolving for health failure patients in China

Improved versions of our new digital platform for heart failure disease management in China have been developed since April, 2020 rollout.

Read More
2020

December

Media Release / Dec 18, 2020

Novartis receives complete response letter from U.S. FDA for inclisiran

Read More
Media Release / Dec 17, 2020

Novartis builds on commitment to addressing need in neuropsychiatric disorders with Cadent Therapeutics acquisition

Read More
Media Release / Dec 16, 2020

Novartis investigational oral therapy iptacopan (LNP023) receives FDA Breakthrough Therapy Designation for PNH and Rare Pediatric Disease Designation for C3G

Read More
Media Release / Dec 16, 2020

Novartis announces positive FDA Advisory Committee recommendation for use of Entresto® to treat patients with HFpEF

Read More

Related Links

Novartis Annual Reporting Suite

Read and download the Annual Review, the Annual Report and Form 20-F, and the Novartis in Society ESG report.

Learn More